选择性环氧合酶-2抑制剂在肿瘤放疗中的应用

Application of selective cyclooxygenase-2 inhibitors in tumor radiotherapy

环氧合酶-2（COX-2）是花生四烯酸生物合成前列腺素的限速酶，在多种恶性肿瘤中高表达，在其发生、发展过程中发挥重要作用，而且与恶性肿瘤预后密切相关，目前已成为潜在的治疗靶点之一。实验研究发现选择性COX-2抑制剂可通过多种分子途径提高恶性肿瘤的放疗增敏性，对正常组织体现出放疗保护作用，是极具前景的放疗调节剂，其分子机制仍需继续深入研究。

Cyclooxygenase-2 （COX-2）, the rate-limited enzyme that converts arachidonic acid into prostaglandin, has been found overexpression in many malignant tumors. The overexpression of COX-2 plays an important role in tumor genesis and progression and is closely associated with tumor prognosis, so this enzyme has become one of the potential therapeutic targets. Experimental studies reveal that selective COX-2 inhibitors can enhance the tumor radiosensitivity through a variety of molecular pathways and have a protective effect for normal tissues. Selective COX-2 inhibitors are promising radiotherapy modifiers and the underlying molecular mechanisms still need to be further studied.